DelveInsight s Sandhoff Disease Pipeline Insight 2026 report provides comprehensive insights about 5 companies and 5 pipeline drugs in Sandhoff Disease pipeline landscape It covers the Sandhoff Disease pipeline drug profiles including clinical and nonclinical stage products It also covers ... • Venglustat: Sanofi Venglustat is a novel, oral investigational therapy that has the potential to slow the progression of certain diseases by inhibiting abnormal glycosphingolipid (GSL) accumulation. GSLs are cellular building blocks whose abnormal accumulation is implicated in several rare diseases, responsible for both cell dysfunction and disease progression.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Sandhoff Disease. Press release - DelveInsight Business Research LLP - Sandhoff Disease Clinical Trial Drug Development Pipeline Expands with Contributions from 5+ Key Companies | DelveInsight - published on openPR.com The Sandhoff disease market size was valued at USD 10.18 billion in 2023, driven growing interest in gene therapy as a potential curative approach across the major markets. The market size is anticipated to grow at a CAGR of 5.87% during the forecast period of 2024-2032 and attain a value of USD 17 billion by 2032. Sandhoff Disease: Sandhoff disease is a rare, inherited genetic disorder characterized by the harmful accumulation of ... "Sandhoff Disease Treatment Market Is Growing At A Steady Cagr During Forecast Period". Pune, India - December 2025 - The global Sandhoff Disease Market, valued at USD 29.6 million in 2024, is expected to reach USD 72.4 million by 2034, growing at a 9.4% CAGR (2025-2034), according to Exactitude Consultancy. Market growth is driven by increasing R&D in rare neurodegenerative disorders, rising investment in gene therapy, and supportive regulatory incentives for orphan drug development.

A recent study explores adult-onset Sandhoff disease, revealing a motor neuron disease phenotype through patient-derived models. This research provides new mechanistic insights that could inform future therapeutic strategies.

Researchers have successfully generated and characterized induced pluripotent stem cell lines from patients with Tay-Sachs and Sandhoff disease. This advancement may facilitate further studies into the pathophysiology and potential therapies for these lysosomal storage disorders.